ADMA Biologics, Inc.

ADMA

US0008991046

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2024 BST			5-day change	1st Jan Change
13.29 ^USD	-3.20%		+10.75%	+194.03%

07-09	Cantor Fitzgerald Adjusts Price Target on ADMA Biologics to $15 From $10, Maintains Overweight Rating	MT
07-01	ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 3000E Value Index	CI

ADMA BIOLOGICS, INC. : Results of Operations and Financial Condition (form 8-K)

January 19, 2022 at 01:32 pm

Item 2.02. Results of Operations and Financial Condition

On January 19, 2022, ADMA Biologics, Inc. (the "Company") issued a press release announcing its preliminary unaudited fourth quarter and full year 2021 revenues and providing a 2022 business update. A copy of the press release is furnished herewith as Exhibit 99.1.*

Latest news about ADMA Biologics, Inc.

Cantor Fitzgerald Adjusts Price Target on ADMA Biologics to $15 From $10, Maintains Overweight Rating	07-09	MT
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 3000E Value Index	06-30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 3000E Index	06-30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell Microcap Index	06-30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 3000 Value Index	06-30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 2500 Value Index	06-30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell Small Cap Comp Value Index	06-30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell Microcap Growth Index	06-30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 3000E Growth Index	06-30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell 2000 Value Index	06-30	CI
ADMA Biologics, Inc.(NasdaqGM:ADMA) dropped from Russell Microcap Value Index	06-30	CI
Mizuho Securities Raises Price Target on ADMA Biologics to $14 From $12, Maintains Buy Rating	06-20	MT
Adma Biologics Insider Sold Shares Worth $2,548,580, According to a Recent SEC Filing	06-17	MT
HC Wainwright Adjusts ADMA Biologics' Price Target to $10 From $7.50, Maintains Buy Rating	05-10	MT
Cantor Fitzgerald Adjusts ADMA Biologics' Price Target to $10 From $8, Maintains Overweight Rating	05-10	MT
ADMA Biologics Shares Rise After Company Swings to Q1 Earnings, Lifts 2024 Guidance	05-10	MT
ADMA Biologics Swings to Q1 Earnings, Revenue Rises; Lifts 2024 Guidance	05-10	MT
ADMA Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q1 Revenue $81.9M, vs. Street Est of $77.3M	05-09	MT
ADMA Biologics, Inc. Revises Earnings Guidance for the Full Year 2024 and 2025	05-09	CI
Transcript : ADMA Biologics, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer	04-02	CI
HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating	03-26	MT
Adma Biologics Insider Sold Shares Worth $2,803,741, According to a Recent SEC Filing	03-20	MT
Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam	03-11	CI

Chart ADMA Biologics, Inc.

Duration

Period

More charts

Company Profile

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for ADMA Biologics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.29 USD

Average target price

13.75 USD

Spread / Average Target

+3.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ADMA BIOLOGICS, INC.	+194.03%	3.08B
CSL LIMITED	+8.54%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+11.97%	43.89B
BIOGEN INC.	-11.76%	33.24B
UCB	+80.10%	29.36B
BIOMARIN PHARMACEUTICAL INC.	-12.20%	16.08B
INCYTE CORPORATION	+4.00%	14.68B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.90%	12.87B
ALTEOGEN INC.	+178.17%	10.55B
SWEDISH ORPHAN BIOVITRUM AB	+1.80%	8.83B

Biopharmaceuticals